礼来

Eli Lilly's 15min chart sees Bollinger Bands Narrowing, KDJ Death Cross triggered.

Eli Lilly's 15-minute chart shows RSI oversold and KDJ golden cross

Eli Lilly

Johnson & Johnson

Sanofi

Large Drugmakers Show Resilience Amid Industry Challenges

Eli Lilly: BMO Capital raises PT to $1200, maintains Outperform rating

Catalyst<ul> <li>Most analysts rate LLY Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 0 bullish).</li> <li>Fund flow trends are negative across medium, large, and extra-large order sizes.</li></ul>

Key Factors

Eli Lilly and Indiana University signed a $40 million agreement to expand clinical trials in Alzheimer's disease, diabetes, cancer, and cell and gene therapy. Eli Lilly's Jaypirca received full FDA approval for treating CLL/SLL patients previously treated with covalent BTK inhibitors. Eli Lilly reduced Zepbound's cash prices to $299-$449 per month to compete with Novo Nordisk's price cuts in the weight-loss drug market. BMO Capital raised Eli Lilly's price target to $1200 and maintained an Outperform rating based on its drug pipeline and growth prospects. Bernstein reaffirmed an Outperform rating on Eli Lilly with a $1300 price target, citing its Alzheimer's potential and obesity market leadership.

Recent Updates

LLY News